Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy

Diabetes/Metabolism Research and Reviews

Volumn 15, Issue 4, 1999, Pages 274-282

  Laight, David W ^a   Carrier, Martin J ^a   Änggård, Erik E ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Angiopathy; Atherosclerosis; Endothelium; Nitric oxide; Oxidant stress

Indexed keywords

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VASCULAR DISEASE;

ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; OXIDATIVE STRESS;

EID: 0032879262     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(199907/08)15:4<274::AID-DMRR46>3.0.CO;2-G     Document Type: Review

References (186)

1. Giugliano D, Paolisso G, Coppla L. Hyperglycaemia and endothelial dysfunction in human diabetes: does oxidative stress play a role? Nutr Metab Cardiovasc Dis 1997; 7: 100-104.
2. Colwell JA. Pharmacological strategies to prevent macrovascular disease in NIDDM. Diabetes 1997; 46: S131-S134.
3. Reaven GM. Banting Lecture 1988; role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
4. Reaven GM. Role of insulin resistance in human disease. Physiol Rev 1995; 75: 473-486.
5. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol 1997; 24: 782-784.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. The multiple risk factor intervention trial research group: diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
7. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347: 949-950.
8. Hsueh WA, Law RE, Saad M, Dy J, Feener E, King G. Insulin resistance and macrovascular disease. Curr Opin Endocrinol Diabetes 1996; 3: 346-354.
9. McCarty MF. Haemostatic concomitants of syndrome X. Med Hypotheses 1994; 44: 179-193.
10. Montalescot G, Choussat R, Collet JP, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19: H11-H17.
11. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med 1998; 105: 485-575.
12. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1685.
13. Burchfiel CM, Reed DM, Marcus EB. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions: An autopsy study from the Honolulu Heart Program. Am J Epidemiol 1993; 137: 1328-1340.
14. Czyzk A, Krolewski AS, Szablowska S. Clinical course of myocardial infarction among diabetic patients. Diabetes Care 1980; 3: 526-529.
15. Jaap AJ, Tooke JE. Pathophysiology of microvascular disease in NIDDM. Clin Sci 1995; 89: 3-12.
16. Tooke JE, Shore AC, Cohen RA, Kluft C. Diabetic angiopathy: tracking down the culprits. J Diabetes Complications 1996; 10: 173-181.
17. Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 1997; 46: S101-S103.
18. Kamide K, Nagano M, Nakano N, et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996; 9: 1165-1171.
19. Shinozaki K, Hattori Y, Suzuki M, et al. Insulin resistance as an independent risk factor for carotid artery wall intima thickening in vasospastic angina. Arterioscler Thromb Vasc Biol 1997; 11: 3302-3310.
20. Mohan IK, Das UN. Oxidant stress, antioxidants and nitric oxide in non-insulin dependent diabetes mellitus. Med Sci Res 1997; 25: 55-57.
21. Giugliano D, Paolisso G, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
22. Tribe RM, Poston L. Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction? Vasc Med 1996; 1: 195-206.
23. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels and incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210.
24. Facchini F, Chen Y-DI, Clinkingbeard C, Jeppesen J, Reaven GM. Insulin resistance, hyperinsulinemia, and dyslipidemia in non-obese individuals with a family history of hypertension. Am J Hypertens 1992; 5: 694-699.
25. Stout RW. Hyperinsulinaemia and atherosclerosis. Diabetes 1996; 45: S45-S46.
26. Ito H, Harano Y, Suzuki M, et al. Risk factor analyses for macrovascular complication in nonobese NIDDM patients. Diabetes 1996; 45: S19-S23.
27. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996; 45: S65-S66.
28. Lopes-Virella MF, Virella G. Cytokines, modified lipoproteins and arteriosclerosis in diabetes. Diabetes 1996; 45: S40-S44.
29. Taniguchi N, Kaneto H, Asahi M, et al. Involvement of glycation and oxidative stress in diabetic macroangiopathy. Diabetes 1996; 45: S81-S83.
30. Giugliano D, Acampora R, D'Onofrio F. Medical hypothesis: cardiovascular complications of diabetes mellitus - from glucose to insulin and back. Diabetes Metab 1994; 20: 445-453.
31. Lüscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20: II-3-II-10.
32. Haller H. Endothelial function. Drugs 1997; 53: 1-10.
33. De Meyer GRY, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997; 4: 325-342.
34. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
35. Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Int Med Res 1994; 235: 317-327.
36. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease Am J Med 1998; 105: 32S-39S.
37. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809-1819.
38. Hsueh WA, Quinones MJ, Creager MA. Endothelium in insulin resistance and diabetes. Diabetes Rev 1997; 5: 343-352.
39. Cooke JP. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin Cardiol 1997; 20: II-45-II-51.
40. Schachter M. The pathogenesis of atherosclerosis. Int J Cardiol 1997; 62: S3-S7.
41. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996; 33: 181-194.
42. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997; 18: E19-E29.
43. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1990; 362: 801-809.
44. Williams KJ, Tabas I. The response to retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9: 471-474.
45. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
46. Radomski MW, Salas E. Nitric oxide-biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atheroscler 1995; 118: S69-S80.
47. Bult H. Nitric oxide and atherosclerosis: possible implications for therapy. Mol Med Today 1996; 2: 510-518.
48. Matthys KE, Bult H. NO function in atherosclerosis. Med Inflamm 1997; 6: 3-21.
49. Osborne JA, Siegman M, Sedar AW, Mooers SU, Lefer AM. Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. Am J Physiol 1989; 256: C591-C597.
50. Matz J, Anderson TLG, Ferns GAA, Änggård EE. Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit. Atheroscler 1994; 110: 241-249.
51. Stewart-Lee AL, Forster LA, Nourooz-Zadeh J, Ferns GAA, Änggård EE. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler Thromb 1994; 14: 494-499.
52. Laight DW, Matz J, Caesar B, Carrier MJ, Änggård EE. Investigation of endogenous nitric oxide vascular function in the carotid artery of cholesterol-fed rabbits. Br J Pharmacol 1996; 117: 1471-1474.
53. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
54. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolaemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995; 75: 75B-81B.
55. Maxwell SRJ. Prospects for the use of antioxidant therapies. Drugs 1995; 49: 345-361.
56. Darley-Usmar V, Halliwell B. Blood radicals. Reactive nitrogen species, transition metal ions, and the vascular system. Pharm Res 1996; 13: 649-662.
57. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature 1986; 329: 454-458.
58. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1994; 89: 87-102.
59. Münzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 1997; 22: 158-172.
60. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
61. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
62. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 23: 118-126.
63. De Zwart LL, Meerman JHN, Commandeur JNM, Vermeulen NPE. Biomarkers of free radical damage: applications in experimental animals in humans. Free Rad Biol Med 1999; 26: 202-226.
64. Pritchard KAJ, Groszek L, Smalley DM, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1994; 77: 354-357.
65. Daugherty A, Roselaar SE. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc Res 1995; 29: 297-311.
66. Graham A, Hogg B, Kalyanaraman, O'Leary V, Darley-Usmar V, Moncada S. Peroxynitrite modification of LDL leads to recognition by the macrophage scavenger receptor. FEBS Lett 1993; 330: 181-185.
67. Wolff SP. Diabetes mellitus and free radicals. Br Med Bull 1993; 49: 642-652.
68. 2α levels are elevated in individuals with NIDDM. FEBS Lett 1995; 368: 225-229.
69. Singh S, Melkani GC, Rani C, Gaur SPS, Arawal V, Agrwal CG. Oxidative stress and metabolic control in non-insulin dependent diabetes mellitus. Indian J Biochem Biophys 1997; 34: 512-517.
70. Ceriello A, Falleti E, Motz E, et al. Hyperglycaemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidant stress. Horm Metab Res 1998; 30: 146-149.
71. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinol 1972; 90: 1320-1330.
72. Laight DW, Kengatharan KM, Gopaul NK, Änggård EE, Carrier MJ. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol 1998; 125: 895-901.
73. Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and NIDDM. Diabet Med 1996; 13: 715-719.
74. Ceriello A, Bortolotti N, Crescentini A, et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 1998; 28: 329-333.
75. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
76. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative nodification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994; 94: 771-778.
77. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321-H326.
78. Schmidt AM, Hori O, Brett J, Yan SD, Wautier J-L, Stern D. Cellular receptors for advanced glycation end products. Arterioscler Thromb 1994; 14: 1521-1528.
79. Wautier J-L, Zoukouirian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. J Clin Invest 1996; 97: 238-243.
80. Bierhaus A, Ziegler R, Nawroth PP. Molecular mechanisms of diabetic angiopathy-clues for innovative therapeutic interventions. Horm Res 1998; 50: 1-5.
81. Ceriello A, Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Diabetes 1996; 45: 471-477.
82. Haffner SM, Agil A, Mykkanen L, Stern MP, Jialal I. Plasma oxidisability in subjects with normal glucose tolerance, impaired glucose tolerance and NIDDM. Diabetes Care 1995; 18: 646-653.
83. Ceriello A, Bortolotti N, Falleti E, et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 1997; 20: 194-197.
84. Ceriello A, Bortolotti N, Pirisi M, et al. Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care 1997; 20: 1589-1593.
85. Aguirre F, Martin I, Grinspon D, et al. Oxidative damage, plasma antioxidant capacity and glycaemic control in elderly NIDDM patients. Free Rad Biol Med 1998; 24: 580-585.
86. Paolisso G, D'Amore A, Volpe C, et al. Evidence for a relationship between oxidative stress and insulin action in NIDDM patients. Metab 1994; 43: 1426-1429.
87. Paolisso G, Giugliano D. Oxidative stress and insulin action: is there a relationship? Diabetologia 1996; 39: 357-363.
88. Laight DW, Desai KM, Gopaul NK, Änggård EE, Carrier MJ. Dietary vitamin E reduces oxidant stress and improves insulin action in the obese Zucker rat in vivo. Br J Pharmacol 1998; 125: P114.
89. Kashiwagi A, Asahina T, Nishio Y, et al. Glycation, oxidative stress, and scavenger activity. Diabetes 1996; 45: S84-S86.
90. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Rad Biol Med 1993; 16: 383-391.
91. Graier WF, Posch K, Wascher TC, Kostner GM. Role of superoxide anions in changes of endothelial vasoactive response during acute hyperglycaemia. Horm Metab Res 1997; 29: 622-626.
92. Galvan AQ, Muscelli E, Catalano C, et al. Insulin decreases circulating vitamin E levels in humans. Metab 1996: 45: 998-1003.
93. De Fronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
94. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
95. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA . Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circ 1996; 93: 1107-1113.
96. Wardle EN. Vascular permeability in diabetics and implications for therapy. Diabetes Res Clin Pract 1994; 23: 135-139.
97. Wascher TC, Toplak H. Endothelial dysfunction and diabetic angiopathy. Diabetologia 1994; 37: 1167-1168.
98. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in NIDDM. Ann Med 1996; 28P: 371-380.
99. Huszka M, Kaplar M, Rejto L, et al. The association of reduced endothelium-derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res 1997; 86: 173-180.
100. Schrör K. Blood vessel wall interactions in diabetes. Diabetes 1987; 46: S115-S118.
101. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
102. Reymer PWA, Gagne E, Groenemayer BE, et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995; 10: 28-30.
103. Pinkney JH, Coen DA, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 16: S9-S13.
104. Vischer UM. Insulin resistance and the regulation of vascular tone: is insulin a vasodilator? Eur J Endocrinol 1998; 138: 262-263.
105. Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998; 32: S54-S61.
106. Makimattila S, Virkamaki A, Groop PH, et al. Chronic hyperglycaemia impairs endothelial function and insulin sensitivity via different mechanisms in IDDM. Circ 1996; 94: 1276-1282.
107. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycaemia attenuates endothelium-dependent vasodilation in humans in vivo. Circ 1998; 97: 1695-1701.
108. Pieper GM, Meier DA, Hager SR. Endothelial dysfunction in a model of hyperglycaemia and hyperinsulinaemia. Am J Physiol 1995; 269: H845-H850.
109. Akbari CM, Saouaf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A. Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycaemia. J Vasc Surg 1998; 28: 687-694.
110. Haller H, Drab M, Luft FC. The role of hyperglycaemia and hyperinsulinaemia in the pathogenesis of diabetic angiopathy. Clin Nepropathy 1996; 46: 246-255.
111. O'Brien SF, Russell JC. Insulin resistance and vascular wall function: lessons from animal models. Endocrinol Metab 1997; 4: 155-162.
112. Kotchen TA, Reddy S, Zhang HY. Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat. Am J Hypertens 1997; 10: 1020-1026.
113. Katakam PV, Ujhelyi MR, Hoenig ME, Miller AW. Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. Am J Physiol 1998; 27: R788-R792.
114. Richardson M, Schmidt AM, Graham SE, Achen B, DeReske M, Russell JC. Vasculopathy and insulin resistance in the JCR : LA-cp rat. Atherosclerosis 1998; 138: 135-146.
115. Andrews TJ, Laight DW, Änggård EE, Carrier MJ. Pharmacological action of insulin to inhibit endothelium-dependent vasodilation in the obese Zucker rat perfused hindlimb in situ. Br J Pharmacol 1998; 125: P117.
116. Ono H, Umeda F, Inoguchi T, Ibayashi H. Glucose inhibits prostacyclin production by cultured aortic endothelial cells. Thromb Haemost 1988; 60: 174-177.
117. Zeiher AM. Endothelial vasodilator dysfunction: pathogenic link to myocardial ischaemia or epiphenomenon? Lancet 1996; 348: S10-S12.
118. Tesfamariam B, Brwon ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85: 929-932.
119. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF. High glucose increases NO synthase expression and superoxide anion generation in human aortic endothelial cells. Circ 1997; 96: 25-28.
120. Yamaguchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H. Enhanced secretion of endothelin 1 by elevated glucose levels from cultured bovine endothelial cells. FEBS Lett 1990; 267: 16-18.
121. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306-310.
122. Hu R-M, Levin ER, Pedram A, Frank HJL. Insulin stimulates the production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42: 351-358.
123. Perfetto F, Tarquini R, de Leonardis V, Piluso A, Lombardi V, Tarquini B. Angiopathy affects circulating endothelin-1 levels in Type 2 diabetic patients. Acta Diabetol 1995; 32: 263-267.
124. Perfetto F, Tarquini R, Tapparini L, Tapparini B. Influence of NIDDM on plasma ET-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 1998; 12: 187-192.
125. Bertello P, Veglio F, Pinna G, et al. Plasma endothelin in NIDDM patients with and without complications. Diabetes Care 1994; 17: 574-577.
126. Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev 1998; 14: 171-175.
127. De Mattia G, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens 1998; 67: 983-988.
128. Mombouli J-V, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 1995; 35: 679-705.
129. Velasquez MT, Bhathena SJ, Striffler JS, Thibault M, Scalbert E. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metab 1998; 47: 7-11.
130. Anderson S. Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab 1998; 24: 406-411.
131. Giugliano D, Marfella R, Acampora R, Giunta R. Coppola L, D'Onofrio F. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998; 21: 631-636.
132. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999; 10: S30-S39.
133. 2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 1996; 271: H159-H165.
134. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalysed mechanism. Proc Natl Acad Sci U S A 1990; 87: 9383-9387.
135. Morrow JD, Roberts LJ. Quantification of noncylcooxygenase derived prostanoids as a marker of oxidant stress. Free Rad Biol Med 1991; 10: 195-200.
136. 2α. Br J Pharmacol 1996; 119: 1276-1280.
137. Mobert J, Becker BF, Zahker S, Gerlach E. Haemodynamic effects of isoprostanes in isolated guinea-pig hearts. J Cardiovasc Pharmacol 1997; 29: 789-794.
138. 2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmacol 1995; 26: S51-S52.
139. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest 1994; 94: 1172-1179.
140. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.
141. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998; 41: 369-379.
142. Taddei S, Virdis A, Mattel P, Natali A, Ferrannini E, Salvettie A. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circ 1995; 92: 147-152.
143. Taddei S, Salvetti A. Insulin and vascular reactivity. Nutr Metab Cardiovasc Dis 1997; 7: 117-123.
144. Lembo G, Iaccarino G, Vecchione C, Rendina V, Parrella L, Trimarco B. Insulin modulation of beta-adrenergic vasodilator pathway in human forearm. Circ 1996; 93: 1403-1410.
145. Walker AB, Savage MW, Dores J, Williams G. Insulin-induced attenuation of noradrenaline-mediated vasoconstriction in resistance arteries from Wistar rats is nitric oxide dependent. Clin Sci 1997; 92: 147-152.
146. Laight DW, Kaw AV, Carrier MJ, Änggård EE. Pharmacological modulation of endothelial function by insulin in the rat aorta. J Pharm Pharmacol 1998; 50: 1117-1120.
147. Laakso M, Edelam SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992; 41: 1076-1083.
148. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced symoathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994; 93: 2365-2371.
149. Shoemaker JK, Bonen A. Vascular actions of insulin in health and disease. Can J App Physiol 1995; 20: 127-154.
150. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996; 97: 2601-2610..
151. Kinoshita J, Tanaka Y, Tojima T, Onuma T, Kawamori R. Suppression of insulin-induced vasodilation in insulin resistant NIDDM patients. Diabetologia 1997; 40: P1007.
152. Walker AB, Dores J, Buckingham RE, Savage MW, Williams G. Impaired insulin induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci 1997; 93: 235-241.
153. White MF, Kahn CR. The insulin signalling system. J Biol Chem 1994; 269: 1-4.
154. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998; 41: 569-576.
155. Baron AD. Insulin and the vasculature-old actors, new roles. J Investig Med 1996; 44: 406-412.
156. Walker AB, Buckingham RE, Williams G. Impaired insulin-induced vasodilatation in insulin resistant fatty Zucker rats: the basis of hypertension? Diabetes 1995; 44: 173A.
157. Laight DW, Kaw AV, Carrier MJ, Änggård EE. Regulation of endothelial function by insulin in the aorta of the obese/lean Zucker rat in vitro. Br J Pharmacol 1997; 122: P154.
158. Lembo G, Morella A, Lanni F, Rozza F, Trimarco B. Vascular insulin resistance in hypertension. Nutr Metab Cardiovasc Dis 1997; 7: 124-126.
159. Taddei S, Salvetti A. Pathogenic factors in hypertension endothelial factors. Clin Exp Hypertens 1996; 18: 323-335.
160. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circ 1993; 87: 1468-1474.
161. Ganrot PO. Insulin resistance syndrome: possible key role of blood flow in resting muscle. Diabetologia 1993; 36: 876-879.
162. Yudkin JS. The Deidesheimer meeting: significance of classical and new risk factors in NIDDM. J Diabetes Complications 1997; 11: 100-103.
163. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
164. Hogikyan RV, Halter JB, Galecki AT, Greene DA, Pi HB, Supiano MA. Specific impairment of endothelium-dependent vasodilation in subjects with Type II diabetes independent of obesity. J Clin Endocrinol Metab 1998; 83: 1946-1952.
165. Wiernsperger N. Vascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypotheses and facts. Diabetes Metab Rev 1994; 10: 287-307.
166. Baron AD, Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96: 786-779.
167. Baron AD. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996; 45: S105-S109.
168. Petrie JR, Ueda S, Webb DJ, Elliott HL, Cornell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with importance for pathogenesis of cardiovascular disease. Circulation 1996; 93: 1331-1333.
169. Petrie JR, Cleland SJ. Insulin sensitivity and endothelial function: a physiological relationship with pathophysiological significance? Nutr Metab Cardiovasc Dis 1997; 7: 113-116.
170. Avogaro A, Piarulli F, Valerio A, et al. Forearm nitric oxide balance, vascular relaxation and glucose metabolism in NIDDM patients. Diabetes 1997; 46: 1040-1046.
171. Utriainen T, Makimattila S, Virkamaki A, Bergholm R, Yki-Jarvinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 1996; 39: 1477-1482.
172. Nuutila P, Raitakari M, Laine H, et al. Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O] water and [18F] fluoro-deoxyglucose and positron emission tomography. J Clin Invest 1996; 97: 1741-1747.
173. Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanism of insulin resistance in IDDM: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 1991; 73: 637-643.
174. Castillo C, Bogardus C, Bergman R, Thuillez P, Lillioja S. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J Clin Invest 1994; 93: 10-16.
175. Miles PDG, Levisetti M, Reichart D, Khoursheed M, Moossa AR, Olefsky JM. Kinetics of insulin action in vivo: identification of rate limiting steps. Diabetes 1995; 44: 947-953.
176. Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80: 415-424.
177. Wascher TC. Endothelial transport processes and tissue metabolism: evidence for microvascular endothelial dysfunction in insulin-resistant diseases? Eur J Clin Invest 1997; 27: 831-835.
178. Natali A. Skeletal muscle blood flow and insulin action. Nutr Metab Cardiovasc Dis 1997; 7: 105-109.
179. Laine H, Yki-Jarvinen H, Kirvela O, et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 1998; 101: 1156-1162.
180. King PA, Horton ED, Hirshman MF, Horton ES. Insulin resistance in obese Zucker rat (fa/fa) skeletal muscle is associated with a failure of glucose transporter location. J Clin Invest 1996; 90: 1568-1575.
181. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM. Mol Cell Biochem 1998; 182: 153-160.
182. Bloomgarden ZT. Insulin resistance: current concepts. Clin Ther 1998; 20: 216-231.
183. Stern MP. Do NIDDM and cardiovascular disease share common antecedents? Ann Intern Med 1996; 124: 110-116.
184. Goodfellow J, Owens D, Henderson A. Cardiovascular syndrome X, endothelial dysfunction and insulin resistance. Diabetes Res Clin Pract 1996; 31: S163-S171.
185. Botker HE, Frobert O, Moller N, Christiansen E, Schmitz O, Bagger JP. Insulin resistance in cardicac syndrome X and variant angina: influence of physical capacity and circulating lipids. Am Heart J 1997; 134: 229-237.
186. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol 1998; 25: 175-184.